Novo­cure fails PhI­II in plat­inum-re­sis­tant ovar­i­an can­cer

Novo­cure’s ovar­i­an can­cer treat­ment failed to meet the pri­ma­ry end­point of over­all sur­vival in a Phase III tri­al, send­ing the New Jer­sey biotech’s stock price …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER